This kit is used for genotyping human UGT1A1*6 and *28 from genomic DNA extracted from patients' peripheral blood. This Irinotecan is an inactive precursor drug that exerts antitumor effects by converting to active metabolites in the liver. Polymorphisms of the UGT1A1*6 and *28 gene in patients cause accumulation of the active metabolites leading to severe toxic drug reaction. The test results can provide guidance for personalized clinical treatment of Irenotican.
Product Advantages
1、Recommended by the clinical guidelines
2、High accuracy: having a unique internal reference design
3、Easy to use and fast turn-around
2、High accuracy: having a unique internal reference design
3、Easy to use and fast turn-around
Target group
1、Colorectal cancer
2、Small cell lung cancer
3、Pancreatic cancer
4、Patients with various solid tumors such as ovarian cancer
2、Small cell lung cancer
3、Pancreatic cancer
4、Patients with various solid tumors such as ovarian cancer
